Economic Impact of Preoperative Meloxicam IV Administration in Total Knee Arthroplasty: A Randomized Trial Sub-Study.
Richard D BerkowitzRichard SteinfeldAlexander P SahVamshi Ruthwik AnupindiDrishti R ShahMitchell DeKovenKatharine CoyleStewart W McCallumRandall J MackErin CoyleAlex FreyerWei DuLibby K BlackPublished in: Journal of pain & palliative care pharmacotherapy (2021)
We evaluated the economic impact associated with preoperative meloxicam IV 30 mg vs placebo administration among adult total knee arthroplasty (TKA) recipients enrolled in Phase IIIB NCT03434275 trial. Data on total hospital costs and length of stay (LOS) obtained from the trial were compared between meloxicam IV 30 mg and placebo groups. Patients in the meloxicam IV 30 mg vs placebo group (n = 93 vs 88) incurred an adjusted $2,266 (95% CI: -$1,035, $5,116; p = 0.1689) lower total hospital costs and an adjusted 8.6% (95% confidence interval [CI]: -2.0%, 18.1%; p = 0.1082) shorter LOS. While statistically non-significant, based on 95% CIs, the results from this sub-study may suggest a favorable impact associated with meloxicam IV 30 mg on hospital costs and LOS.
Keyphrases
- total knee arthroplasty
- phase iii
- healthcare
- clinical trial
- total hip
- patients undergoing
- end stage renal disease
- double blind
- acute care
- study protocol
- open label
- adverse drug
- newly diagnosed
- electronic health record
- phase ii
- randomized controlled trial
- peritoneal dialysis
- young adults
- emergency department
- kidney transplantation